Edition:
United States

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

4.40USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.40
Open
$4.35
Day's High
$4.50
Day's Low
$4.35
Volume
96,474
Avg. Vol
92,108
52-wk High
$6.45
52-wk Low
$2.58

Chart for

About

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's... (more)

Overall

Beta: 0.27
Market Cap(Mil.): $146.90
Shares Outstanding(Mil.): 33.39
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 35.70
ROE: -- 16.55 15.40

BRIEF-Adamis Pharmaceuticals Subsidiary Develops Compound To Manage Ulcers In Horses

* US COMPOUNDING, A SUBSIDIARY OF ADAMIS PHARMACEUTICALS, DEVELOPS A UNIQUE COMPOUND TO MANAGE ULCERS IN HORSES Source text for Eikon: Further company coverage:

Dec 06 2017

BRIEF-Adamis Pharmaceuticals Announces Submission Of Investigational New Drug (Ind) Application To The FDA

* ADAMIS PHARMACEUTICALS ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE FDA FOR NEW PRODUCT CANDIDATE FOR THE TREATMENT OF OPIOID OVERDOSE Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Dec 04 2017

BRIEF-Adamis Pharma Submits Prior Approval Supplement To FDA For The Pediatric Version Of Symjepi

* ADAMIS PHARMACEUTICALS SUBMITS PRIOR APPROVAL SUPPLEMENT TO FDA FOR THE PEDIATRIC VERSION OF SYMJEPI

Nov 29 2017

Competitors

  Price Chg
GlaxoSmithKline plc (GSK.L) 1,295.00 +4.50

Earnings vs. Estimates